ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and Development

PartnershipPositive

AI Analysis

Summary

ERS Genomics and Sai Life Sciences announced a CRISPR/Cas9 license agreement to advance precision genome editing in drug discovery and development. The agreement provides Sai Life Sciences access to foundational CRISPR/Cas9 intellectual property.

Importance:6/10

Sentiment:

0.60

CRISPRlicensinggenome editingdrug discoveryintellectual property

Related Companies

$DTIL $CRSP $GBCMD

Read the original article

Published by PR Newswire Pharma on September 22, 2026 12:30 PM

Read Original